[go: up one dir, main page]

NO952334L - Fremstilling av stabile sink-insulin-analog krystaller - Google Patents

Fremstilling av stabile sink-insulin-analog krystaller

Info

Publication number
NO952334L
NO952334L NO952334A NO952334A NO952334L NO 952334 L NO952334 L NO 952334L NO 952334 A NO952334 A NO 952334A NO 952334 A NO952334 A NO 952334A NO 952334 L NO952334 L NO 952334L
Authority
NO
Norway
Prior art keywords
preparation
insulin analog
stable zinc
analog crystals
crystals
Prior art date
Application number
NO952334A
Other languages
English (en)
Norwegian (no)
Other versions
NO952334D0 (no
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO952334(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO952334D0 publication Critical patent/NO952334D0/no
Publication of NO952334L publication Critical patent/NO952334L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO952334A 1994-06-16 1995-06-13 Fremstilling av stabile sink-insulin-analog krystaller NO952334L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
NO952334D0 NO952334D0 (no) 1995-06-13
NO952334L true NO952334L (no) 1995-12-18

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952334A NO952334L (no) 1994-06-16 1995-06-13 Fremstilling av stabile sink-insulin-analog krystaller

Country Status (29)

Country Link
US (1) US5504188A (pt)
EP (1) EP0692489B1 (pt)
JP (1) JP3595607B2 (pt)
KR (1) KR100369951B1 (pt)
CN (1) CN1184234C (pt)
AT (1) ATE233278T1 (pt)
AU (1) AU697794B2 (pt)
BR (1) BR9502798A (pt)
CA (1) CA2151563C (pt)
CO (1) CO4410205A1 (pt)
CZ (1) CZ286066B6 (pt)
DE (1) DE69529708T2 (pt)
DK (1) DK0692489T3 (pt)
ES (1) ES2188637T3 (pt)
FI (1) FI952930A7 (pt)
HU (1) HUT73495A (pt)
IL (1) IL114152A (pt)
IN (1) IN178919B (pt)
MY (1) MY130551A (pt)
NO (1) NO952334L (pt)
NZ (1) NZ272358A (pt)
PE (1) PE21896A1 (pt)
PL (1) PL180968B1 (pt)
RO (1) RO113529B1 (pt)
RU (1) RU2156257C2 (pt)
SI (1) SI0692489T1 (pt)
TW (1) TW379228B (pt)
YU (1) YU39595A (pt)
ZA (1) ZA954942B (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU6611898A (en) * 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
WO2000023099A1 (en) * 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
PT1121144E (pt) * 1998-10-16 2002-11-29 Novo Nordisk As Preparados de insulina concentrada estavel para administracao pulmonar
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
DK1772464T3 (da) * 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
SI3300721T2 (sl) 2003-11-20 2025-05-30 Novo Nordisk A/S Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
BRPI0618649A2 (pt) 2005-11-17 2011-09-06 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007127704A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ATE538116T1 (de) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2164458A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101939023B (zh) * 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
EP2391218B1 (en) 2009-01-28 2020-03-18 Smartcells, Inc. Conjugate based systems for controlled drug delivery
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
EP2464655B1 (en) * 2009-08-11 2017-02-15 Biocon Limited Chromatographic processes
RU2603752C2 (ru) 2011-02-01 2016-11-27 Ново Нордиск А/С Очистка инсулина
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
US10124040B2 (en) 2014-08-26 2018-11-13 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
KR20220161422A (ko) 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (pt) *
BE533252A (pt) *
BE533298A (pt) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE93238T1 (de) * 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
HU217684B (hu) * 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
IL114152A (en) 1999-12-31
KR100369951B1 (ko) 2003-03-28
PL309099A1 (en) 1995-12-27
CZ286066B6 (cs) 2000-01-12
HUT73495A (en) 1996-08-28
CN1128271A (zh) 1996-08-07
CO4410205A1 (es) 1997-01-09
DE69529708D1 (de) 2003-04-03
AU697794B2 (en) 1998-10-15
ZA954942B (en) 1996-12-17
HU9501715D0 (en) 1995-08-28
IL114152A0 (en) 1995-10-31
FI952930A0 (fi) 1995-06-14
ES2188637T3 (es) 2003-07-01
EP0692489B1 (en) 2003-02-26
PL180968B1 (pl) 2001-05-31
MY130551A (en) 2007-06-29
AU2168195A (en) 1996-01-04
RU2156257C2 (ru) 2000-09-20
CN1184234C (zh) 2005-01-12
PE21896A1 (es) 1996-06-15
RU95110107A (ru) 1997-05-10
EP0692489A1 (en) 1996-01-17
TW379228B (en) 2000-01-11
JP3595607B2 (ja) 2004-12-02
CA2151563C (en) 2007-08-07
KR960000922A (ko) 1996-01-25
FI952930L (fi) 1995-12-17
IN178919B (pt) 1997-07-19
JPH08169899A (ja) 1996-07-02
NO952334D0 (no) 1995-06-13
DE69529708T2 (de) 2003-10-16
RO113529B1 (ro) 1998-08-28
CZ154195A3 (en) 1996-02-14
NZ272358A (en) 1996-12-20
YU39595A (sh) 1997-08-22
FI952930A7 (fi) 1995-12-17
SI0692489T1 (en) 2003-06-30
ATE233278T1 (de) 2003-03-15
US5504188A (en) 1996-04-02
BR9502798A (pt) 1996-06-04
DK0692489T3 (da) 2003-03-31
CA2151563A1 (en) 1995-12-17

Similar Documents

Publication Publication Date Title
NO952334L (no) Fremstilling av stabile sink-insulin-analog krystaller
DE69637988D1 (de) Pharmazeutische Zubereitung enthaltend Pioglitazone und Glimepiride zur Verwendung in der Behandlung von Diabetes
NO176754C (no) Fremgangsmåte og anlegg for biologisk rensing av avlöpsvann
HUT46542A (en) Process for production of medical preparatives containing bifilar rns and virus-inhibitors applicable for human treatment of virus infection
AU591212B2 (en) New improved orthopedic/orthotic splint materials
NZ227429A (en) Wound healing composition comprising purified platelet-derived growth factor and purified transforming growth factor alpha and method of use
NO891896D0 (no) Fremgangsmaate og innretning for behandling av medisinsk spesialavfall.
AT399657B (de) Anlage zur pflege von ärztlichen und zahnärztlichen instrumenten
AU1069888A (en) Patient limb positioning apparatus and toroidal surgical shield
AU2355288A (en) Implantable blood oxygen sensor and method of use
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
NO996265D0 (no) Behandling av diabetes med rosiglitazon og insulin
IL87566A0 (en) Medical composition for the treatment of diabetes comprising a benzamide derivative
FI895730A7 (fi) Apinan transformoivan kasvutekijä-B1:n kloonaus ja ilmentäminen
KR900012933A (ko) 당뇨병 및 과혈당증 치료제로 유용한 화합물 및 이의 제조방법
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
HUT43588A (en) Process for production of new optically active compounds and medical compounds containing thereof
AU4553593A (en) Treatment of diabetes using phosphorylated insulin
HUT42477A (en) Process for production of active substances decreasing blood-pressure and medical preparatives containing thereof
DK204390D0 (da) Metode til behandling af taender og tandstoettevaev
GB2230443B (en) Treatment of sleep apnoea
RO102987B1 (ro) Procedeu de purificare a insulinei
GB9005050D0 (en) Treatment of diabetes
AU2183088A (en) Method and apparatus for the recovery of purification and recovery of human growth hormone
IE883282L (en) Treatment of bone diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application